GOSSAMER BIO INC (GOSS)
US38341P1021 - Common Stock
Taking everything into account, GOSS scores 1 out of 10 in our fundamental rating. GOSS was compared to 588 industry peers in the Biotechnology industry. GOSS has a bad profitability rating. Also its financial health evaluation is rather negative. GOSS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year GOSS has reported negative net income.
GOSS had a negative operating cash flow in the past year.
In the past 5 years GOSS always reported negative net income.
In the past 5 years GOSS always reported negative operating cash flow.
1.2 Ratios
GOSS's Return On Assets of -57.65% is in line compared to the rest of the industry. GOSS outperforms 44.01% of its industry peers.
GOSS's Return On Equity of -286.49% is on the low side compared to the rest of the industry. GOSS is outperformed by 73.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -57.65% | ||
| ROE | -286.49% | ||
| ROIC | N/A |
ROA(3y)-69.97%
ROA(5y)-59.46%
ROE(3y)-791.59%
ROE(5y)-500.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GOSS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GOSS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for GOSS has been increased compared to 5 years ago.
Compared to 1 year ago, GOSS has an improved debt to assets ratio.
2.2 Solvency
GOSS has an Altman-Z score of -5.93. This is a bad value and indicates that GOSS is not financially healthy and even has some risk of bankruptcy.
GOSS's Altman-Z score of -5.93 is on the low side compared to the rest of the industry. GOSS is outperformed by 65.41% of its industry peers.
A Debt/Equity ratio of 3.14 is on the high side and indicates that GOSS has dependencies on debt financing.
The Debt to Equity ratio of GOSS (3.14) is worse than 83.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.14 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.93 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 5.94 indicates that GOSS has no problem at all paying its short term obligations.
GOSS has a better Current ratio (5.94) than 62.33% of its industry peers.
A Quick Ratio of 5.94 indicates that GOSS has no problem at all paying its short term obligations.
GOSS has a better Quick ratio (5.94) than 62.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.94 | ||
| Quick Ratio | 5.94 |
3. Growth
3.1 Past
GOSS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.27%, which is quite impressive.
EPS 1Y (TTM)49.27%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q64.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 18.47% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y44.41%
EPS Next 2Y21.77%
EPS Next 3Y18.21%
EPS Next 5Y18.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GOSS. In the last year negative earnings were reported.
Also next year GOSS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as GOSS's earnings are expected to grow with 18.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.77%
EPS Next 3Y18.21%
5. Dividend
5.1 Amount
No dividends for GOSS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GOSSAMER BIO INC
NASDAQ:GOSS (4/26/2024, 7:00:02 PM)
After market: 0.7 +0.03 (+4.79%)0.668
0 (-0.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap150.69M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -57.65% | ||
| ROE | -286.49% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.14 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.94 | ||
| Quick Ratio | 5.94 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)49.27%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y44.41%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y